Management of dyslipidaemia by Raal, FJ
C a r d i ovascular disease, p a rticularly coro-
n a ry art e ry disease (CAD), remains the
leading cause of morbidity and mort a l i t y
wo r l d w i d e . Ye t , despite compelling epi-
d e m i o l o gical and clinical data demonstrat-
ing conclusively that dyslipidaemia, p a rt i c-
ularly elevated low-density lipoprotein
cholesterol (LDLC) leve l s , c o rr e l ates with
heightened CAD mortality and that lipid-
l owe ring interventions with either lifestyle
m o d i f i c ation or drug therapy can reduce
r ates of cardiovascular eve n t s , we remain a
‘ hy p e r c h o l e s t e r o l a e m i c, atherogenic soci-
e t y ’ who are becoming increasingly more
s e d e n t a ry and more obese.
Although this review will concentrat e
mainly on currently available drug therapy
for the management of dyslipidaemia, i t
must be emphasised that non-pharm a c o-
l o gical therapy plays a vital role. M a ny
p atients with mild or moderate dyslipi-
daemia will be able to achieve optimum
lipid levels with lifestyle modification alone
a n d , if they are able to maintain a healthy
l i f e s t y l e , will not require lifelong lipid-
modifying therapy.
The management of a patient with dyslipi-
daemia depends on the type of lipid dis-
t u r b a n c e , on whether the elevated lipid
l e vel is pri m a ry or secondary, and on the
presence of other risk fa c t o rs for CAD and
absolute ri s k . The measurement of seru m
lipids should therefore form part of a full
clinical examinat i o n .
The following serves as a check list that
must be considered in each pat i e n t :
• A c c o m p a nying modifiable risk fa c t o rs
for CAD, e . g . hy p e rt e n s i o n , s m o k i n g,
d i a b e t e s , should be sought and treat e d .
• Underlying secondary causes of dyslipi-
d a e m i a , e . g . excess alcohol intake,
hy p o t hy r o i d i s m , should be identified and
c o rr e c t e d .
• The goal of treatment should be clearly
explained to the patient and the ri s k s
c o n f e rred by untreated dyslipidaemia
should be emphasised.
NON - PH A RM ACOLOGIC A L
T HERA PY  (LIFESTYLE 
MODIFIC AT ION )
E p i d e m i o l o gical and clinical trial evidence
e va l u ating diet and CAD prevention show s
t h at at least three dietary strat e gies are
e f f e c t i ve , namely 
• substituting non-hy d r o g e n ated unsat u-
r ated fats (mono- and polyunsat u r at e d
fats) for sat u r ated and trans-fat s
• increasing consumption of omega-3 fat t y
acids from fish and plant sources
• consuming a diet high in fru i t s , ve g e t a-
b l e s , nuts and whole unrefined gr a i n s.
Such diets, together with regular phy s i c a l
a c t i v i t y, avoidance of smoking, and main-
taining a healthy we i g h t , will probably pre-
vent or at least reduce the prevalence of
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thesis based on stud-
ies in these subjects.
Management of 
dyslipidaemia
As society becomes increasingly sedentary and
obese, the management of dyslipidaemia
becomes ever more important for the general
p r a c t i t i o n e r .
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We remain a ‘hyper-
c h o l e s t e r o l a e m i c ,
atherogenic society’ who
are becoming increas -
ingly more sedentary
and more obese.
In a patient consuming a typical
We s t e rn diet who complies we l l
with a prudent lipid-lowe ring diet
and achieves and maintains ideal
body weight (BMI < 27 kg/m2) , t h e
average fall in LDLC could be up
to 20% (i.e. a decrease in LDLC of
1 - 2 mmol/l). There is, h owe ve r ,
considerable individual va ri ation in
r e s p o n s i ve n e s s , and the ave r a g e
reduction in LDLC in response to
a change in diet is usually more
m o d e s t .
INDIC AT IONS FOR DRUG
T HERA PY
C a r d i ov a s c u l a r
The main indication for lipid-modi-
fying medication is to reduce car-
d i ovascular ri s k . D rug therapy
should be considered when non-
p h a rm a c o l o gical means have fa i l e d
to reduce the lipid levels to within
the target range (Table I). W h e n
global risk for the individual is high
l i p i d - l owe ring drugs are used.T h i s
is a lway s in conjunction with ongo-
ing lifestyle modificat i o n .
There are 3 main cardiova s c u l a r
i n d i c ations for lipid-modifying dru g
t h e r a p y :
• S e v ere genetic dyslipidaemia ,
e . g . familial hy p e r c h o l e s t e r o-
l a e m i a , familial combined hy p e r-
lipidaemia and dysbetalipopro-
t e i n a e m i a . These subjects usually
h ave a positive family history of
s e vere dyslipidaemia and prema-
ture CAD, together with clinical
m a r k e rs of genetic dyslipidaemia.
• S e c o n d a r y prev e n t i o n . Pat i e n t s
with manifest CAD, c e r e b r ova s-
cular disease or peripheral va s c u-
lar disease. Diabetics are at high
c a r d i ovascular risk and type 2
diabetes is now considered a
CAD risk equivalent in the USA
(NCEP III).
• P ri m a r y prev e n t i o n . S u b j e c t s
at high risk for CAD (e.g. hy p e r-
t e n s i ves) in whom the calculat e d
1 0 - year risk for an acute coronary
e vent is gr e ater than 20% (or
more than 30% in young pat i e n t s
if their risk is projected to 60
ye a rs of age). Recent evidence
suggests that such high-ri s k
p atients will benefit from lipid-
l owe ring (statin) therapy irr e s p e c-
t i ve of baseline LDLC leve l s.
N o n - c a r d i ov a s c u l a r
The most serious non-cardiova s c u-
lar complication of dyslipidaemia is
the development of acute pancreat i-
t i s. This is seen in subjects with
s e vere hy p e rt ri g l y c e ri d a e m i a
( t ri g l y c e ride (TG) >15 mmol/l).
Ideally such patients should be
r e f e rred to a lipid specialist.
The basic principles are to control
or reve rse possible secondary fa c-
t o rs (e.g. alcohol excess, d i a b e t e s ) ,
introduction of a ve ry low - fat diet
and lipid-modifying drug therapy.
S t atin therapy is not appropri ate for
the treatment of severe hy p e r-
t ri g l y c e ridaemia and fibrates are the
d rugs of choice.
L IPID - MODIFY ING DRUGS
S e veral drugs are currently ava i l-
able for the treatment of dyslipi
daemia on the South A f rican mar-
k e t .
HMG CoA reductase inhibitors or
statins — atorvastatin, fluvastatin,
pravastatin, simvastatin
The HMG CoA reductase
i n h i b i t o rs or ‘ s t at i n s ’ h ave revo l u-
tionised the therapy of dyslipi-
daemia and are now the drugs of
choice for the management of
hy p e r c h o l e s t e r o l a e m i a . R e s u l t s
from 6 major clinical trials invo l v-
ing over 30 000 subjects have docu-
mented a decrease in both CAD
and total morbidity and mort a l i t y,
reductions in myocardial infa r c-
t i o n s , r e va s c u l a ri s ation procedures,
stroke and peripheral vascular dis-
e a s e . These drugs act by competi-
t i vely inhibiting the rat e - l i m i t i n g
enzyme of cholesterol synthesis —
HMG CoA reductase. C h o l e s t e r o l
is essential for normal intracellular
metabolic processes. Therefore to
c o m p e n s ate for the decreased ava i l-
ability of intracellular cholesterol,
the cell increases its LDL receptor
n u m b e r , resulting in increased utili-
s ation of circulating cholesterol and
reducing the serum cholesterol
l e ve l .
The statins are the most powe r f u l
of the cholesterol-lowe ring dru g s
ava i l a b l e . S e rum cholesterol is
reduced by 20 - 45%. LDLC is
decreased by 25 - 55%;TGs are
m o d e r ately reduced by 10 - 30%
and HDLC is elevated by 5 - 15%.
It is important to remember that
reductions in LDLC are log-linear,
so that with each doubling of the
dose of a statin one does not get a
doubling of LDLC reduction.
R at h e r , each doubling of the dose
of any statin only results in a fur-
ther 6% reduction in LDLC.
Cost effectiveness of the different
s t atins can be determined by com-
p a ring prices of equivalent doses of
s t atins as shown in Table II. T h e
s t atins are equally effective in treat-
ing patients with familial and non-
familial hy p e r c h o l e s t e r o l a e m i a .
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Total cholesterol ≤ 5 mmol/l
Triglycerides ≤ 1.5 mmol/l
HDL cholesterol ≥ 1.2 mmol/l
LDL cholesterol ≥ 3 mmol/l
Table I. Optimal fasted lipid profile
A g e , g e n d e r , or body weight do not
influence the response to the stat i n s
s i g n i f i c a n t l y. Tolerance does not
d e ve l o p, and the response is main-
tained indefinitely during therapy.
The statins are mainly hepat i c a l l y
excreted and doses therefore do not
h ave to be decreased in renal fa i l-
u r e . The drugs are easily adminis-
tered and are ve ry well tolerat e d .
They are best gi ven at bedtime.
H owe ve r , at o rva s t atin can be
administered at any time of the day
because of its long half-life.
H e p at o t oxicity (transient 3%, p e r-
sistent 0.5%) and myo p at hy 
(< 0.5%) are the two major side-
effects of the stat i n s. The incidence
of myo p at hy is increased in the
e l d e r l y, in the presence of liver or
renal disease, or with the concomi-
tant administration of other dru g s
such as cy c l o s p o ri n e , f i b r at e s , e ry-
t h r o mycin and nicotinic acid.
Fatal rhabdomyolysis is howe ver a
ve ry rare event with an incidence of
less than one death per million pre-
s c ri p t i o n s. Frequently rhabdomyo l-
ysis is the result of a potentially
avoidable drug interaction.
S t atins are therefore remarkably
safe dru g s. The ratio betwe e n
s aved and lost lives among stat i n -
t r e ated patients over 10 ye a rs of use
can be estimated at about 
100 000 to 1 —  undoubtedly justi-
fying lifelong clinical use of stat i n s
in those who wa rrant it.
Bile acid sequestrants (or anion
exchange resins) — cholestyra-
m i n e
This is a we l l - t ried drug that is
widely used in the treatment of
familial hy p e r c h o l e s t e r o l a e m i a .
Cholestyramine is not absorbed
and its function is to reduce intesti-
nal reabsorbtion of bile acids.
Increased production of bile acids
by the liver therefore ensues,
depleting liver cells of cholesterol,
thereby inducing increased LDL
receptor activity on the liver cells.
As a result LDL catabolism is
increased and plasma LDLC leve l s
fall by 15 - 30%.
HDLC may increase by 3 - 5%.
Because of increased hepat i c
lipoprotein synthesis stimulated by
resin therapy, t ri g l y c e rides may
h owe ver increase moderat e l y.
Resins are therefore contraindicat-
ed as monotherapy in persons with
hy p e rt ri g l y c e ri d a e m i a .
The sequestrants are not absorbed
from the gastrointestinal tract and
therefore lack systemic tox i c i t y.
They are particularly suitable for
t r e ating younger pat i e n t s , e s p e c i a l l y
c h i l d r e n , and women consideri n g
p r e g n a n cy.
U n f o rt u n ately these agents are
u n p a l at a b l e , leading to poor pat i e n t
c o m p l i a n c e . Common side-effects
include constipation (> 3 0 % ) , g a s-
trointestinal (GIT) discomfort
( 2 0 % ) , nausea (8%) and bloating 
( 9 % ) . More rarely diarr h o e a , s t e at-
o rr h o e a , intestinal obstruction and
hyperchloraemic acidosis can
o c c u r.
These agents also interfere with
a b s o rption of anionic dru g s , e . g .
wa r fa ri n , t hy r oxine and lipid-solu-
ble vitamins. Antacids can amelio-
r ate the dyspepsia, while increasing
fluid intake and a high-fibre diet or
stool softener can help counteract
c o n s t i p at i o n .
Nicotinic acid (niacin)
Nicotinic acid, or niacin, a B-gr o u p
v i t a m i n , is a potent lipid-lowe ri n g
agent which decreases LDL and
VLDL production. N i c o t i n a m i d e
is not effective in lowe ring seru m
cholesterol (SC) and cannot substi-
tute for nicotinic acid. N i c o t i n i c
acid appears to act by inhibiting
lipolysis and by reducing the flux of
free fatty acids to the live r , l i m i t i n g
VLDL and LDL production.
Nicotinic acid may also reduce
h e p atic synthesis of apoB1 0 0, a n
essential component of V L D L . T h e
reduced hepatic synthesis of these
lipoproteins leads to a  reduction of
the plasma concentrations of
t ri g l y c e ri d e , and to a lesser extent
cholesterol (as LDL is deri ve d
mainly from V L D L ) . S e rum cho-
lesterol levels decrease by 20 - 30%
and TGs by 20 - 60%. HDLC can
increase by 20 - 30%.The dose
needed is 2 - 6 g/day (100 mg tabs
only are available in South A f ri c a ,
therefore one would require 20 - 6 0
t a b s / d ay in divided doses). S i d e -
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% reduction
Atorvastatin Simvastatin Pravastatin Fluvastatin TC LDLC
10 20 40 22 27
10 20 40 80* 27 34
20 40 32 41
40 80 37 48
80 42 55
TC = total cholesterol; LD LC = low-density lipoprotein cholesterol.
*Extended release.
Table II. Comparative efficacy of currently available statins (mg/day)
effects at the doses needed to be
e f f e c t i ve are significant and the
d rug can often not be tolerat e d .
The adve rse effects include flushing
( > 9 5 % ) , p ru ri t u s , r a s h , a c a n t h o s i s
n i gri c a n s , t oxic amblyo p i a , d i z z i-
n e s s , GIT discomfort , hy p e ru ri-
caemia with acute gout, i m p a i r e d
glucose tolerance and increased
l i ver enzymes.
The incidence of side-effects can be
decreased by taking the tablets with
meals and by starting with small
doses increasing the dose gr a d u a l l y
over a 3 - 4-week peri o d . Pat i e n t s
must be encouraged not to take the
tablets intermittently as this aggr a-
vates the side-effects. A s p i rin taken
a p p r ox i m ately an hour before can
also ameliorate side-effects. O ve r
40% of patients are unable to
remain on therapy due to side-
e f f e c t s. Sustained-release prepara-
tions of nicotinic acid have been
used which cause fewer side-effects,
but are unfort u n ately also less
e f f e c t i ve in lipid reduction. R a r e
cases of fulminant hepatitis have
also been reported with sustained-
release preparat i o n s.
C o n t r a i n d i c ations to the use of
nicotinic acid include peptic ulcera-
t i o n , h e p atic disease and gouty
a rt h ri t i s. It is also necessary to
monitor blood glucose, l i ver func-
tion and uric acid levels duri n g
t h e r a p y.
Fibrates — fenofibrate, bezafi-
brate, gemfibrozil
These drugs appear to work mainly
by increasing the activity of
lipoprotein lipase (thereby increas-
ing VLDL clearance) and may also
decrease VLDL production. T h e y
act by stimulating the nuclear tran-
s c ription factor peroxisome prolif-
e r at o r - a c t i vated receptor-alpha
( P PA R -α) . Their main effect is on
plasma tri g l y c e rides which can
decrease by 20 - 50%. HDLC can
increase by 10 - 35%. SC can
h owe ver also be decreased due to
decreased VLDL synthesis and
increased LDL clearance. L D L C
is usually decreased modestly by 
5 - 20%.
The fibrates are well tolerated and
side-effects are uncommon (< 3 %
of pat i e n t s ) . Side-effects include
n a u s e a , abdominal pain and rarely
myo p at hy, i m p o t e n c e , raised live r
function tests (LFTs) and alopecia.
These drugs are renally excreted
and therefore impaired renal func-
tion is a relat i ve contraindication to
f i b r ate dru g s. Gemfibrozil is least
reliant on the kidney for its excre-
tion but its limiting effect on glu-
c u r o n i d ation is thought to be the
reason for its interaction with
s t atins to promote rhabdomyo l i s i s.
A summary of the lipid-modifying
effects of the different drugs as we l l
as the present drugs of choice for
the treatment of dyslipidaemia are
s h own in Tables III and IV.
Combination therapy
In patients with severe dyslipi-
daemia single drug therapy in com-
b i n ation with diet may fail to
a c h i e ve an adequate reduction in
the lipid leve l s. In these situat i o n s
c o m b i n ation therapy may be wa r-
r a n t e d .
In patients with predominant
hypercholesterolaemia the most
e f f e c t i ve combination curr e n t l y
available is a statin plus a resin.
With this combinat i o n , a gr e at e r
u p r e g u l ation of LDL receptors
o c c u rs as a result of both a
decrease in cholesterol synthesis
and an increase in cholesterol elim-
i n at i o n . Reductions in LDLC are
therefore gr e ater than with either
agent alone.This combination can
decrease serum LDLC by 50 -
6 0 % . The triple combination of
an HMG CoA reductase inhibitor
+ resin + nicotinic acid can reduce
LDLC by up to 70%.
In patients with mixed hy p e r l i p i-
daemia or predominant hy p e r-
t ri g l y c e ri d a e m i a , a combination of
a statin plus a fibrate or nicotinic
acid may be more effective .
While combination drug therapy
m ay prove essential to achieve
desirable lipid leve l s , it must be
remembered that side-effects are
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% %
decrease decrease % increase % change Reduced Long-term
TC LDLC HDLC TG CHD risk safety
HMG CoA 15 - 45% 25 - 55% 5 - 15% ↓10 - 30% Yes Yes
reductase 
inhibitors
Bile acid 10 - 25% 15 - 30% 3 - 5% ↑0 - 10% Yes Yes
resins
Nicotinic 5 - 20% 5 - 25% 15 - 35% ↓20 - 50% Yes Yes
acid
Fibrates 0 - 15% 5 - 20% 10 - 35% ↓20 - 50% Yes Yes
TC = total cholesterol; LDLC = low-density lipoprotein cholesterol; TG = triglycerides; CHD = coronary heart disease; HDLC = high-density lipopro-
tein cholesterol.
Table III. Summary of the effects of the major lipid-lowering agents
more likely and that costs become
s u b s t a n t i a l .
OT HER AGEN T S
Plant stanol/sterols
These act to lower cholesterol
absorbtion by interfering with cho-
lesterol assimilation in micelles in
the gut. They are added to mar-
g a rines and at a dose of 2 - 3 g/day
can lower LDLC by 6 - 15% with
little or no change in HDLC or T G
l e ve l s.
Po l i c o s a n o l
Policosanol is a mixture of higher
p ri m a ry aliphatic alcohols isolat e d
from sugar cane wa x ; its main com-
ponent is octacosanol. The exact
mechanism of action of policosanol
is unknown but at doses of 10 - 20
m g / d ay it can lower LDLC by 15 -
2 9 % . D ata on efficacy determ i n e d
by clinical end-points such as car-
diac mortality are howe ver lacking.
W H AT’S ON THE HORI-
Z ON ?
More potent statins
Two new stat i n s , r o s u va s t atin and
p i t ava s t at i n , are being deve l o p e d .
In clinical studies with rosuva s t at i n
reductions in LDLC of 45 - 70%
h ave been achieve d .
E ze t i m i b e
Ezetimibe is the first in a new class
of cholesterol absorbtion inhibitors
t h at potently and selectively inhibit
d i e t a ry cholesterol absorption at
the brush border of the intestinal
epithelium without affecting the
absorbtion of tri g l y c e ride or fat - s o l-
uble vitamins. Unlike resins, G I T
side-effects are uncommon.
Ezetimibe at a dose of 10 mg/day
can reduce LDLC by 15 - 25%.
When used in combination with
s t at i n s , ezetimibe produces signifi-
cant additional reductions in
LDLC (±20%) with no increase in
a d ve rse eve n t s.
CONCLUSIONS
Management of dyslipidaemia
requires appropri ate lifestyle modi-
f i c ation and, where indicat e d , l i p i d -
modifying drug therapy. Safe and
e f f e c t i ve drug therapy is now ava i l-
able for the management of most
d y s l i p i d a e m i a s.
There is now substantial evidence
to show that appropri ately pre-
s c ribed lipid-modifying drug thera-
py can lower morbidity and mort a l-
ity from CAD and improve ove r a l l
s u rv i va l , both in subjects with
established cardiovascular disease
and in those at high risk for deve l-
oping cardiovascular disease.
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Statin (only effective in mild to moderate hypertriglyceridaemia)
*First choice.
Table IV. Present drugs of choice for the treatment
of dyslipidaemia
IN A NUTSHELL
Dyslipidaemia, particularly an ele-
vated LDL-cholesterol level, is the
major risk factor for cardiovascular
disease.
Lifestyle modification is essential
and must be applied to all patients
with dyslipidaemia.
Patients with genetic dyslipidaemia,
established cardiovascular disease,
diabetes, and those at high cardio-
vascular risk warrant lipid-modify-
ing drug therapy.
Appropriately prescribed lipid-mod-
ifying drug therapy can lower car-
diovascular morbidity and mortality
and improve overall survival.
Statins are the most effective
agents  for the treatment of pre-
dominant hypercholesterolaemia.
Fibrates are more effective for the
treatment of hypertriglyceridaemia.
Combination therapy may be
required for the treatment of
severe dyslipidaemia but side-
effects are more likely and costs
become substantial.
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